Talk Bio

Through Flux and Fluidity, FDA Keeps Coming Back to Rare Disease: 2026 Policy Shifts and Approvals in Rare Disease Space

Busy FDA gives rare disease sector complementary pathways, unanswered questions – 2026 snapshot

FDA Accelerates Rare Disease Drug Approvals with New Frameworks and Record 2025 Approvals

FDA Launches New Submission Program for Rare Disease Gene Therapies via CDER and CBER